25725-11-5

Basic information

• Product Name: 2-METHYL-2-PROPAN-D9-OL
• Synonyms: 2-METHYL-2-PROPAN-D9-OL;TERT-BUTYL-D9 ALCOHOL;TERT-BUTANOL (D9);TERT-BUTANOL-D9,OH;2-(Methyl-d3)-2-propan-d6-ol;2-Propan-1,1,1,3,3,3-d6-ol,2-(methyl-d3)-;2-Methyl-2-propan-d9-ol, tert-Butyl-d9 alcohol;tert-Butan-d9-ol
• CAS NO: 25725-11-5
• Molecular Formula: C₄H₁₀O
• Molecular Weight: 83.18
• Mol File: 25725-11-5.mol
• Article Data: 2

Chemical Properties

• Melting Point: 23-26 °C(lit.)
• Boiling Point: 83 °C(lit.)
• Flash Point: 11 °C
• Appearance: /
• Density: 0.868 g/mL at 25 °C
• CAS DataBase Reference: 2-METHYL-2-PROPAN-D9-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYL-2-PROPAN-D9-OL(25725-11-5)
• EPA Substance Registry System: 2-METHYL-2-PROPAN-D9-OL(25725-11-5)

Safety Data

• Hazard Codes: F,Xn
• Statements: 11-20-36/37
• Safety Statements: 9-16-46
• RIDADR: UN 1120 3/PG 2
• Hazardous Substances Data: 25725-11-5(Hazardous Substances Data)

Usage

Uses

tert-Butyl-d9 Alcohol (CAS# 25725-11-5) is a useful isotopically labeled research compound.

Upstream product

• 666-52-4 [⁽²⁾H₆]acetone 
• 41251-37-0 methyl-d3-magnesium iodide 

Downstream Products

• 42310-83-8 tert-Butyl-d9 Bromide 
• 6045-08-5 1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-amine 
• 56248-36-3 tert-butylbenzene-d9 
• 918-20-7 tert-butyl chloride-d9 
• 225386-58-3 p-tert-butylphenol-d13 
• 1246816-88-5 2-d-4,6-bis(1,1,1,3,3,3-d₆-2-(methyl-d₃)propan-2-yl)phenol 

Relevant articles and documents

Diphenylamino pyrimidine compound for inhibiting kinase activity

The invention provides a diphenylamino pyrimidine compound for inhibiting the kinase activity, and particularly provides a medicinal composition of a substituted diphenylamino pyrimidine compound andapplication thereof. The compound is a compound as shown in a formula (I) in the specification, or pharmaceutically acceptable salt, prodrug, hydrate thereof or solvent compound, crystal form, N-oxideand various diastereomers thereof. The compound can be used for treating diseases which can be treated with JAK2 kinase inhibitors.